{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:20:47Z","timestamp":1774416047369,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2026,3]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n \n Dupilumab is reimbursed in France for adult patients with moderate\u2010to\u2010severe atopic dermatitis (\n AD<\/jats:sc>\n ), in cases of failure, intolerance or contraindication to cyclosporin A (CsA). The French National Authority for Health requested collection of data on dupilumab\u2010treated patients' characteristics and prior systemic treatments to examine conformity with the reimbursement scope.\n <\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n \n This study aimed to describe characteristics of adult patients initiating dupilumab for\n AD<\/jats:sc>\n and their prior lines of systemic treatments with a focus on CsA.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Our dual approach combined information from two databases: the SNDS database allowing access to nationwide prescriptions for dupilumab (DUPIXAM study) and data collected by a sponsor\u2010initiated multicentre, cross\u2010sectional, observational study on patients initiating dupilumab for\n AD<\/jats:sc>\n (MOVE study).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n From December 2019 to May 2021, 594 eligible patients were included in the MOVE study. In parallel, from March 2019 to December 2020, 3216 adult patients with presumed indications of moderate\u2010to\u2010severe\n AD<\/jats:sc>\n were extracted from SNDS. Patients' characteristics were quite similar: median age was >\u200934\u2009years old and they were gender balanced. More than 69% of MOVE patients had severe\n AD<\/jats:sc>\n and 82.8% had at least one atopic comorbidities. Previous systemic treatments were used by over 62.8% of patients, of whom over 75.0% had received CsA. Among the 25.0% without previous CsA, the indirect combinatory approach made it possible to estimate an unbiased proportion of CsA contraindications in 71.0% of patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This joint analysis provided a detailed view of real\u2010world conditions of dupilumab use in France through the completeness of data, and constitutes a proof of concept that could be extended to address other health\u2010related questions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/fcp.70070","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:14:17Z","timestamp":1770394457000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Use of Dupilumab in Atopic Dermatitis: Observational Study Results Linked to SNDS"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3212-7455","authenticated-orcid":false,"given":"Alain","family":"Dupuy","sequence":"first","affiliation":[{"name":"Department of Dermatology Univ Rennes, CHU Rennes Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Claire","family":"Fougerousse","sequence":"additional","affiliation":[{"name":"Department of Dermatology H\u00f4pital d'Instruction des Arm\u00e9es B\u00e9gin Saint Mand\u00e9 Saint\u2010Mand\u00e9 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre\u2010Andr\u00e9","family":"B\u00e9cherel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Immunology Clinique H\u00f4pital Priv\u00e9 d'Antony Antony France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6714-6643","authenticated-orcid":false,"given":"Catherine","family":"Droitcourt","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Rennes Rennes France"},{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail) Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4119-203X","authenticated-orcid":false,"given":"Sandrine","family":"Kerbrat","sequence":"additional","affiliation":[{"name":"DAMAD SAS Plouzan\u00e9 France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-2783","authenticated-orcid":false,"given":"Aymeric","family":"Mahieu","sequence":"additional","affiliation":[{"name":"Sanofi Winthrop Industrie Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mie","family":"Allali","sequence":"additional","affiliation":[{"name":"Sanofi Winthrop Industrie Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Lise","family":"Vataire","sequence":"additional","affiliation":[{"name":"Sanofi Winthrop Industrie Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Th\u00e9ni\u00e9","sequence":"additional","affiliation":[{"name":"Sanofi Winthrop Industrie Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Helman","sequence":"additional","affiliation":[{"name":"Sanofi Winthrop Industrie Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7663-2053","authenticated-orcid":false,"given":"Jean\u2010Philippe","family":"Lacour","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Universit\u00e9 Nice\u2010C\u00f4te d'Azur, CHU de Nice Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370220"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2019.08.009"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.022"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.017"},{"key":"e_1_2_12_8_1","unstructured":"Transparence HAdSCdl \u201cDupixent \u201d Acc\u00e8s le 10\/12\/2018 Published Avis du 11 juillet 2018. Access https:\/\/www.has\u2010sante.fr\/portail\/upload\/docs\/evamed\/CT\u201016605_DUPIXENT_PIC_INS_avis3_CT16605.pdf."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjs.5550350403"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1992.10475217"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17632"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19447"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18566"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18452"}],"container-title":["Fundamental & Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.70070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.70070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:33:08Z","timestamp":1774413188000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.70070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/fcp.70070"],"URL":"https:\/\/doi.org\/10.1111\/fcp.70070","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2025-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70070"}}